Illustrative image – not actual.Maiva Pharma, a global contract manufacturing organization and contract development and manufacturing organization specialising in sterile injectables, has inaugurated its new manufacturing facility at Shoolagiri in Tamil Nadu.
The facility strengthens the company’s position as a trusted partner for global pharmaceutical and biotechnology firms engaged in the development and manufacturing of complex sterile injectable products, including generics and advanced formulations. Spread across a 22-acre site, the facility has been designed with scalable infrastructure, advanced manufacturing technologies, and robust quality systems to meet current and future global market demands. Once fully developed, it will house six production lines capable of manufacturing a wide range of dosage forms. As part of its Phase 1 expansion, Maiva Pharma has commissioned three manufacturing lines, including a high-speed vial filling line, a combined pre-filled syringe and cartridge line, and a dedicated lyophilization line. The facility is also equipped with advanced quality control chemical laboratories and microbiology labs to ensure comprehensive in-house testing and quality assurance.
A key feature of the facility is its isolator-based manufacturing technology, which enhances sterility assurance, improves operational efficiency, and supports compliance with stringent global regulatory standards for injectable pharmaceuticals. Built in accordance with international regulatory standards, the facility underscores Maiva Pharma’s strong focus on quality and excellence in manufacturing.
